WHAT ONCOLOGY CLINICIANS WANT TO KNOW

Addressing Current Questions and Controversies in the Management of Breast Cancer

When
Wednesday, December 10, 2014 7:30 PM – 9:30 PM
(Dinner buffet to be provided)

Where
San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, Texas
Grand Ballroom (Third Floor)

Faculty
Kimberly L Blackwell, MD
Adam M Brufsky, MD, PhD
Angelo Di Leo, MD, PhD
Kathy D Miller, MD
Eric P Winer, MD

Moderator
Neil Love, MD

Register Today
www.ResearchToPractice.com/Meetings/SA2014

This event is free of charge. However, registration is limited to clinicians in practice. Preregistration is advised as seating is limited.

Participate in interactive polling and Q&A throughout this unique event

Sponsored by Research To Practice.
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Foundation Medicine, Genentech BioOncology, Genomic Health Inc and Lilly.
Copyright © 2014 Research To Practice.
Moderator’s Note

For more than 25 years we have been asking clinical investigators questions in an attempt to provide practicing oncology clinicians with the information they need to better take care of their patients. And while we think we have done a respectable job in tackling this challenging task, we’ve always welcomed the input of audience members, believing that if one person had a question, likely many more had the same one. It is in this spirit that we are pleased to announce this upcoming educational event to be hosted in conjunction with the San Antonio Breast Cancer Symposium.

Leading up to the program, we are inviting clinicians to help us define the content and agenda by submitting challenging cases and/or questions related to the comprehensive management of this complex disease. Our goal is to tailor the panel discussions and clinical research reviews that will form the basis of the activity to address the information and questions obtained from this initiative. If you would like us to run a case or question by our esteemed faculty, please feel free to drop me an email at NLove@ResearchToPractice.com.

For those planning to be in San Antonio, anyone attending the program will be provided with a networked tablet to participate in a premeeting knowledge- and case-based survey, view the presentation slides up close and contribute additional questions. We believe that this will grant all in attendance an opportunity to access the most up-to-date, important and relevant information they truly want (and need) to know.

I hope you will make plans to join us.

Neil Love, MD
Research To Practice
Miami, Florida

Participate in interactive polling and Q&A throughout this unique event
CME Information

Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to:
- Appreciate the similarities and differences between existing genomic assays, and use this information to select an appropriate platform or platforms to assess risk and individualize therapy for patients with invasive and noninvasive early breast cancer (EBC).
- Develop an evidence-based algorithm for the initial and long-term treatment of localized hormone receptor-positive pre- and postmenopausal BC.
- Individualize the selection of evidence-based neoadjuvant and adjuvant chemo-biologic regimens for patients with HER2-overexpressing EBC.
- Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing, recently approved and investigational targeted treatments.
- Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal BC, including the use of endocrine, biologic and chemotherapeutic agents.
- Apply the results of current clinical research to the selection and sequencing of available therapeutics for patients with localized and advanced triple-negative BC.
- Recall emerging research data with next-generation sequencing, and determine the clinical and/or research application for patients with metastatic BC.
- Counsel appropriately selected patients about participation in ongoing BC clinical research.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.
Module 1: Neoadjuvant and Adjuvant Therapy for HER2-Positive Tumors  
— Dr Winer

Faculty Presentation Topics/Questions

- In what clinical situations should patients with localized HER2-positive breast cancer (BC) be referred for medical oncology consultation prior to surgery? In what situations do you consider neoadjuvant systemic therapy equivalent to or better than postoperative treatment?
- What recently completed and ongoing clinical trials are attempting to expand and refine the care of patients with early HER2-positive disease (eg, APT trial, ExteNET, APHINITY, ATEMPT)?

Module 2: Adjuvant Treatment for ER-Positive, HER2-Negative Tumors  
— Dr Miller

Faculty Presentation Topics/Questions

- What is known about the comparative reproducibility of the following genomic assays, their individual prognostic value and their ability to predict benefit from adjuvant chemotherapy: 21-gene Recurrence Score® (OncoType DX®), 70-gene signature (MammaPrint®), PAM50 and IHC4?
- How, if at all, have the recent presentations of the SOFT and TEXT trials changed your approach to the care of premenopausal patients with ER-positive/HER2-negative early BC?
Sample Questions Submitted by Community-Based Clinicians

- If there are 2 small lesions in the same breast, each with a different grade, which one would you send for Oncotype DX? Do we need 2 scores?
- Has Oncotype DX been examined on lymph nodes?
- Is there a role for the Oncotype DX DCIS Score™?
- When would you use MammaPrint instead of Oncotype DX?
- Who doesn’t need extended adjuvant therapy? Should patients with ER-rich disease that is low risk according to Oncotype DX receive only 5 years of therapy?

Module 3: Treatment of HER2-Positive Metastatic Disease — Dr Brufsky

Faculty Presentation Topics/Questions

- In what clinical situations, if any, do you recommend a treatment regimen other than trastuzumab/pertuzumab/taxane as first-line therapy for HER2-positive metastatic disease? What is your usual second-line recommendation?
- In general, what is your treatment approach for a patient who is responding systemically to therapy for HER2-positive metastatic disease and then develops brain metastases?

Sample Questions Submitted by Community-Based Clinicians

- In HER2-positive metastatic BC (mBC) with CNS metastases, does pertuzumab or T-DM1 have any efficacy or would lapatinib-based treatment be the best option?
- Is there a relationship between level of HER2 overexpression and response to HER2-directed therapy?
- Is there an increase in cardiotoxicity associated with pertuzumab in combination with trastuzumab?
- Is there any role for the use of pertuzumab and trastuzumab without chemotherapy in HER2-positive mBC?
- Can a patient with ER-positive, HER2-positive disease who is receiving T-DM1 also receive concurrent endocrine therapy?

Module 4: Management of ER/PR/HER2-Negative Metastatic Disease — Dr Blackwell

Faculty Presentation Topics/Questions

- What clinical trials are currently evaluating PARP inhibitors in metastatic triple-negative BC (TNBC)? What is known about patients with BRCA mutations?
- Is next-generation sequencing clinically relevant? What molecular alterations have been observed in this subset of patients that can help inform clinical trial opportunities?

Sample Questions Submitted by Community-Based Clinicians

- Is there any tissue assay platform you would use to inform the choice of treatment for a young woman with progressive TNBC after an anthracycline, a taxane and gemcitabine?
- Are any ongoing trials investigating immunotherapy in TNBC?
Module 5: Management of ER-Positive, HER2-Negative Metastatic Disease — Dr Di Leo

Faculty Presentation Topics/Questions

- What clinical and patient-specific factors contribute to your decision-making for patients with ER-positive BC who experience relapse while receiving an adjuvant aromatase inhibitor (AI)?
- What clinical trials are currently evaluating CDK inhibitors? What is known about the mechanism of action and clinical activity of these agents when combined with endocrine therapy in patients with ER-positive mBC?
- What other novel agents are being evaluated in combination with hormonal therapy to try to overcome endocrine resistance mechanisms (eg, PI3K inhibitors, histone deacetylase inhibitors)?

Sample Questions Submitted by Community-Based Clinicians

- How would you care for a postmenopausal patient with metastatic ER-positive, HER2-negative lobular carcinoma with extensive bone marrow involvement whose disease is progressing on first-line anastrozole?
- Is there a role for fulvestrant in combination with an AI in patients with ER-positive, HER2-negative mBC, or would you prefer to administer sequential therapy?
- What’s your trigger to treat hypertriglyceridemia associated with everolimus, and how do you treat it?
- What does FDA breakthrough designation mean, and how does it affect the status of palbociclib?

About Research To Practice

Founded and led by medical oncologist Neil Love, MD, Research To Practice (RTP) has provided meaningful, relevant and unbiased educational perspectives for more than 25 years to meet the needs of oncology clinicians and positively affect the care of patients with cancer. RTP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.

All of RTP’s CME activities help bridge the gap between research and patient care and assist practitioners in clinical decision-making by providing ongoing access to the opinions and perspectives of internationally recognized cancer clinical investigators. Using a variety of media and approaches, including audio, web/email, mobile and live formats, RTP creates truly unique CME activities and series that are used by the vast majority of cancer clinicians in the United States and highly respected by others around the world.

To access RTP’s extensive archive of CME activities focused on breast cancer, in addition to numerous other tumor types, please visit www.ResearchToPractice.com.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

This event is free of charge. However, registration is limited to clinicians in practice. Preregistration is advised as seating is limited.

San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone:
(210) 223-1000

Meeting Room: Grand Ballroom (Third Floor)

The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B Gonzalez Convention Center.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.